Literature DB >> 1727062

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

A Mitrakou1, D Kelley, M Mokan, T Veneman, T Pangburn, J Reilly, J Gerich.   

Abstract

BACKGROUND: Insulin resistance and impaired insulin secretion both occur in non-insulin-dependent diabetes (NIDDM), but their relative importance is unclear. Hyperglycemia itself has adverse effects on tissue insulin sensitivity and insulin secretion that make it difficult to distinguish between primary and secondary abnormalities. To avoid this problem we studied subjects with postprandial glucose intolerance but not sustained hyperglycemia.
METHODS: We compared the rate of systemic appearance and disappearance of glucose, the output of endogenous hepatic glucose, splanchnic and muscle uptake of glucose, and plasma insulin and glucagon responses after the ingestion of 1 g of glucose per kilogram of body weight in 15 subjects with impaired glucose tolerance (8 of them nonobese and 7 obese) and in 16 normal subjects (9 nonobese and 7 obese) who were matched for age and weight.
RESULTS: After glucose ingestion the mean (+/- SE) rate of total systemic appearance of glucose was significantly higher in both the nonobese subjects (455 +/- 12 mmol per five hours) and the obese subjects (486 +/- 17 mmol per five hours) with impaired glucose tolerance than in the respective normal subjects (411 +/- 11 and 436 +/- 7 mmol per five hours). This difference was fully accounted for by the reduced suppression of endogenous hepatic glucose in the subjects with impaired glucose tolerance (a reduction of about 28 percent, vs. 48 percent in the normal subjects; P less than 0.01). Despite late hyperinsulinemia, at 30 minutes the subjects with impaired glucose tolerance had smaller increases in plasma insulin and smaller reductions in plasma glucagon (both P less than 0.01). Molar ratios of plasma insulin to plasma glucagon levels correlated inversely (r = -0.62, P less than 0.001) with the rates of systemic glucose appearance; the latter correlated positively (r = 0.72, P less than 0.0001) with peak plasma glucose concentrations.
CONCLUSIONS: Impaired glucose tolerance, the precursor of NIDDM, results primarily from reduced suppression of hepatic glucose output due to abnormal pancreatic islet-cell function. The late hyperinsulinemia may be the consequence of an inadequate early beta-cell response rather than of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727062     DOI: 10.1056/NEJM199201023260104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  116 in total

Review 1.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

2.  Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass.

Authors:  Juris J Meier; Sandra Ueberberg; Simone Korbas; Stephan Schneider
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-02-01       Impact factor: 4.310

3.  Effect of Tang No.1 granule (1) in treating patients with impaired glucose tolerance.

Authors:  Yan WEI; Yu-zhi HONG; Xun YE
Journal:  Chin J Integr Med       Date:  2008-12-12       Impact factor: 1.978

4.  Connexin 36 mediates blood cell flow in mouse pancreatic islets.

Authors:  Kurt W Short; W Steve Head; David W Piston
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

Review 5.  New insights into the role of connexins in pancreatic islet function and diabetes.

Authors:  Nikki L Farnsworth; Richard K P Benninger
Journal:  FEBS Lett       Date:  2014-02-28       Impact factor: 4.124

6.  A novel functional polymorphism (-336A/G) in the promoter of the partitioning-defective protein-6alpha gene is associated with increased glucose tolerance and lower concentrations of serum non-esterified fatty acids.

Authors:  P Weyrich; R Lammers; A Fritsche; F Machicao; H-U Häring; N Stefan
Journal:  Diabetologia       Date:  2005-03-03       Impact factor: 10.122

7.  Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum.

Authors:  Caroline K Kramer; Chang Ye; Anthony J G Hanley; Philip W Connelly; Mathew Sermer; Bernard Zinman; Ravi Retnakaran
Journal:  Diabetologia       Date:  2015-03-12       Impact factor: 10.122

8.  Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes.

Authors:  M Shimodaira; Y Muroya; N Kumagai; K Tsuzawa; K Honda
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

Review 9.  Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Authors:  Baptist Gallwitz
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 10.  Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

Authors:  L C Groop; E Widén; E Ferrannini
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.